Tag Archives: Ralph Snodgrass

The PRES. of VistaGen Therapeutics is Exercising Options

Today it was reported that the PRES. of VistaGen Therapeutics (VTGN – Research Report), Ralph Snodgrass, exercised options to buy 2,500 VTGN shares at $1.50 a share, for a total transaction value of $3,750. The options were close to expired